Molecular Aspects concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

Yury Valdes-Balbin*, Darielys Santana-Mederos, Françoise Paquet, Sonsire Fernandez, Yanet Climent, Fabrizio Chiodo, Laura Rodríguez, Belinda Sanchez Ramirez, Kalet Leon, Tays Hernandez, Lila Castellanos-Serra, Raine Garrido, Guang Wu Chen, Dagmar Garcia-Rivera, Daniel G. Rivera, Vicente Verez-Bencomo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.

Original languageEnglish
JournalACS Central Science
DOIs
Publication statusAccepted/In press - 2021

Cite this